PeptiCRAD

 
 

PeptiCrad is conceived to overcome the biggest limitation of the oncolytic vaccine platform e.i. the virus immune-dominance. 

In fact, our group and other had demonstrated that the treatment of oncolytic viruses has a dual mode-of-action, the oncolysys (direct lysis of the infected tumor cell) and a "vaccine" effect that occurs triggering some degrees of anti-tumor immune response (Figure below).

Naked Oncolytic vaccine

Naked Oncolytic vaccine

Nevertheless the most significant limitation with the naked viruses is that the majority of the immune response is towards the virus and only a small degree of the response is directed towards the tumor.

To overcome this limitation we have developed PeptiCrad, a "virus in tumor's clothing"!

 In fact, PeptiCrad is a virus covered with tumor-specific peptides to promote anti-peptides, hence anti-tumor,  immune response rather anti-virus immune response.

PeptiCrad

PeptiCrad

Compared to naked virus the PeptiCrad technology significantly increase the amount of anti-tumor specific immunity and consequently the overall response.

Comparison of naked vaccine and PeptiCrad in murine melanoma model.

Comparison of naked vaccine and PeptiCrad in murine melanoma model.

See dedicated section on publication to have access to the published manuscript